CU22290A1 - Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal - Google Patents
Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunalInfo
- Publication number
- CU22290A1 CU22290A1 CU90155A CU1990155A CU22290A1 CU 22290 A1 CU22290 A1 CU 22290A1 CU 90155 A CU90155 A CU 90155A CU 1990155 A CU1990155 A CU 1990155A CU 22290 A1 CU22290 A1 CU 22290A1
- Authority
- CU
- Cuba
- Prior art keywords
- hepatitis
- virus
- humans
- antigen
- achieve
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 241000700721 Hepatitis B virus Species 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 208000006454 hepatitis Diseases 0.000 abstract 2
- 231100000283 hepatitis Toxicity 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
ESTA INVENCION ESTA ENMARCADA EN EL CAMPO DE LA INGENIERIA GENETICA Y LA AL ADYUVANTE ADECUADO RESULTA ALTAMENTE INMUNOGENICO EN ANIMALES Y HUMANOS. EL CAMPO DE APLICACION DE ESTE RESULTADO ES PRINCIPALMENTE LA PRODUCCION DE VACUNAS RECOMBINANTES CONTRA EL VIRUS DE LA HEPATITIS B PARA USO EN HUMANOS, AUNQUE EL ANTIGENO ASI OBTENIDO TAMBIEN PUEDE SER UTILIZADO CON FINES DIAGNOSTICOS. BIOTECNOLOGIA Y EN PARTICULAR EN EL DE LA PRODUCCION DE VACUNAS CONTRA EL VIRUS DE LA HEPATITIS B. EL OBJETIVO FUNDAMENTAL DE LA MISMA CONSISTE EN LOGRAR ALTOS NIVELES DE OBTENCION DEL ANTIGENO DE SUPERFICIE DEL VIRUS DE LA HEPATITIS B CON ADECUADA PARTICULACION Y ALTO GRADO DE PUREZA PARA SU EMPLEO EN UNA PREPARACION VACUNAL CON CAPACIDAD INMUNOGENICA INCREMENTADA CON VISTAS A SU UTILIZACION EN HUMANOS. A FIN DE LOGRAR ESTE OBJETIVO SE LLEVA A CABO UN PROCEDIMIENTO CUYO PRIMER PASO CONSISTIO EN LA CREACION DE UN SISTEMA VECTOR-HOSPEDERO ADECUADO MEDIANTE UNA CONSTRUCCION GENETICA PROPIA QUE CONTIENE EL GEN DEL ANTIGENO DE SUPERFICIE DEL VIRUS DE LA HEPATITIS B EN UN CASSETTE DE EXPRESION QUE FUE UTILIZADO PARA LA TRANSFORMACION DE UNA CEPA MUTANTE DE P. PASTORIS HIS- DENOMINADA MP 36. LA CEPA RECOMBINANTE OBTENIDA, C226 ES CRECIDA EN CONDICIONES TALES QUE PERMITEN UNA ALTA PRODUCCION DEL ANTIGENO RECOMBINANT E DE FORMA SOLUBLE, INTRACELULAR Y PARTICULADO, CON UNA TALLA DE 22 NM. POSTERIORMENTE, SE LLEVA UN PROCESO DE EXTRACCION Y PURIFICACION QUE PERMITE LOGRAR, MEDIANTE EL EMPLEO DE UN ANTICUERPO MONOCLONAL DISEÑADO CON ESTE FIN, UN PRODUCTO DE ALTA PUREZA Y HOMOGENEIDAD EL CUAL AL SER ACOPLADO\!
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU90155A CU22290A1 (es) | 1990-10-08 | 1990-10-08 | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
AU85574/91A AU649482B2 (en) | 1990-10-08 | 1991-10-03 | Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation |
DK98202021T DK0864649T3 (da) | 1990-10-08 | 1991-10-07 | Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat |
AT98202021T ATE324451T1 (de) | 1990-10-08 | 1991-10-07 | Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung |
ES91202615T ES2129025T3 (es) | 1990-10-08 | 1991-10-07 | Metodo para la obtencion de un antigeno de superficie recombinante del virus de la hepatitis b (hep b) de capacidad inmunogenica elevada y utilizacion del mismo en un preparado de vacuna. |
DE69130724T DE69130724T2 (de) | 1990-10-08 | 1991-10-07 | Verfahren zur Gewinnung von rekombinantem Hepatitis B Virus (HEP B) Oberflächeantigen |
DK91202615T DK0480525T3 (da) | 1990-10-08 | 1991-10-07 | Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve |
AT91202615T ATE175445T1 (de) | 1990-10-08 | 1991-10-07 | Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen |
DE69133525T DE69133525T8 (de) | 1990-10-08 | 1991-10-07 | Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung |
EP91202615A EP0480525B1 (en) | 1990-10-08 | 1991-10-07 | Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) |
ES98202021T ES2264183T3 (es) | 1990-10-08 | 1991-10-07 | Metodo para obtener antigeno de superficie del virus de la hepatitis b (hep b), recombinante, con capacidad inmunogenica superior y su uso en una preparacion de vacuna. |
EP98202021A EP0864649B1 (en) | 1990-10-08 | 1991-10-07 | Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation |
JP32631091A JP3189212B2 (ja) | 1990-10-08 | 1991-10-08 | 高免疫能を有するb型肝炎ウイルス組換え表面抗原の取得方法 |
GR990400666T GR3029582T3 (en) | 1990-10-08 | 1999-03-04 | Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) |
JP2000392672A JP3242640B2 (ja) | 1990-10-08 | 2000-12-25 | 高免疫能を有するb型肝炎ウイルス組換え表面抗原およびb型肝炎ウイルスワクチン組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU90155A CU22290A1 (es) | 1990-10-08 | 1990-10-08 | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
Publications (1)
Publication Number | Publication Date |
---|---|
CU22290A1 true CU22290A1 (es) | 1995-01-31 |
Family
ID=5459466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU90155A CU22290A1 (es) | 1990-10-08 | 1990-10-08 | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0480525B1 (es) |
JP (2) | JP3189212B2 (es) |
AT (2) | ATE175445T1 (es) |
AU (1) | AU649482B2 (es) |
CU (1) | CU22290A1 (es) |
DE (2) | DE69133525T8 (es) |
DK (2) | DK0864649T3 (es) |
ES (2) | ES2264183T3 (es) |
GR (1) | GR3029582T3 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960001122A (ko) * | 1994-06-09 | 1996-01-25 | 엠. 리몬타 비달 | 재조합 단일사슬 Fv 항체 절편과 B형 간염 바이러스 표면 항원의 면역정제를 위한 그 용도 |
KR960023066A (ko) * | 1994-12-10 | 1996-07-18 | 성재갑 | 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법 |
CU22642A1 (es) * | 1996-12-12 | 2000-12-22 | Ct Ingenieria Genetica Biotech | Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso |
US6436402B1 (en) | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
EP1403274A1 (en) * | 2002-09-30 | 2004-03-31 | Meristem Therapeutics | Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby |
CU23405A1 (es) * | 2003-10-20 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas para uso terapéutico |
JP4936272B2 (ja) * | 2006-02-13 | 2012-05-23 | 独立行政法人科学技術振興機構 | バイオナノカプセルの効率的な精製法 |
CU23740A1 (es) | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
WO2017167317A1 (es) | 2016-03-31 | 2017-10-05 | Centro De Ingenieria Genetica Y Biotecnologia | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
KR102630293B1 (ko) * | 2021-06-21 | 2024-01-29 | 선지호 | 박스 포장 테이프 절단용 칼날유닛과 이를 이용한 박스 포장 테이프 절단장치. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59101426A (ja) * | 1982-11-29 | 1984-06-12 | Green Cross Corp:The | B型肝炎感染予防用ワクチンの製造方法 |
US4624918A (en) * | 1984-07-09 | 1986-11-25 | Genentech, Inc. | Purification process for hepatitis surface antigen and product thereof |
US4895800A (en) * | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
ATE91304T1 (de) * | 1987-02-27 | 1993-07-15 | Merck & Co Inc | Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe. |
US5004688A (en) * | 1988-04-15 | 1991-04-02 | Phillips Petroleum Company | Purification of hepatitis proteins |
NZ228774A (en) * | 1988-04-25 | 1991-05-28 | Phillips Petroleum Co | Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells |
KR900008591B1 (ko) * | 1988-05-13 | 1990-11-26 | 동아제약 주식회사 | 항이디오형 항체를 용출제로 사용하는 면역친화성 크로마토그라프법에 의한 생리활성물질의 정제방법 |
-
1990
- 1990-10-08 CU CU90155A patent/CU22290A1/es unknown
-
1991
- 1991-10-03 AU AU85574/91A patent/AU649482B2/en not_active Ceased
- 1991-10-07 DE DE69133525T patent/DE69133525T8/de not_active Expired - Fee Related
- 1991-10-07 DK DK98202021T patent/DK0864649T3/da active
- 1991-10-07 EP EP91202615A patent/EP0480525B1/en not_active Expired - Lifetime
- 1991-10-07 AT AT91202615T patent/ATE175445T1/de not_active IP Right Cessation
- 1991-10-07 DK DK91202615T patent/DK0480525T3/da not_active Application Discontinuation
- 1991-10-07 ES ES98202021T patent/ES2264183T3/es not_active Expired - Lifetime
- 1991-10-07 ES ES91202615T patent/ES2129025T3/es not_active Expired - Lifetime
- 1991-10-07 AT AT98202021T patent/ATE324451T1/de not_active IP Right Cessation
- 1991-10-07 DE DE69130724T patent/DE69130724T2/de not_active Expired - Fee Related
- 1991-10-07 EP EP98202021A patent/EP0864649B1/en not_active Expired - Lifetime
- 1991-10-08 JP JP32631091A patent/JP3189212B2/ja not_active Expired - Fee Related
-
1999
- 1999-03-04 GR GR990400666T patent/GR3029582T3/el unknown
-
2000
- 2000-12-25 JP JP2000392672A patent/JP3242640B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH0576370A (ja) | 1993-03-30 |
GR3029582T3 (en) | 1999-06-30 |
EP0480525A3 (en) | 1992-09-30 |
ES2264183T3 (es) | 2006-12-16 |
AU649482B2 (en) | 1994-05-26 |
AU8557491A (en) | 1992-04-30 |
EP0864649A2 (en) | 1998-09-16 |
ATE324451T1 (de) | 2006-05-15 |
JP3189212B2 (ja) | 2001-07-16 |
EP0480525A2 (en) | 1992-04-15 |
JP3242640B2 (ja) | 2001-12-25 |
DE69130724T2 (de) | 1999-06-17 |
EP0480525B1 (en) | 1999-01-07 |
DE69133525T2 (de) | 2006-11-23 |
DK0480525T3 (da) | 1999-08-30 |
EP0864649B1 (en) | 2006-04-26 |
ES2129025T3 (es) | 1999-06-01 |
DE69133525T8 (de) | 2007-03-08 |
DK0864649T3 (da) | 2006-08-28 |
JP2001231582A (ja) | 2001-08-28 |
DE69130724D1 (de) | 1999-02-18 |
EP0864649A3 (en) | 1998-11-11 |
ATE175445T1 (de) | 1999-01-15 |
DE69133525D1 (de) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2264563T3 (es) | Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion. | |
JP5570819B2 (ja) | 酵母を含む組成物および酵母を増殖させる方法 | |
CU22290A1 (es) | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal | |
Newcomb et al. | Assembly of the herpes simplex virus capsid: characterization of intermediates observed during cell-free capsid formation | |
Israel et al. | In vitro morphogenesis of phage P22 from heads and base-plate parts | |
ATE132195T1 (de) | Rekombinant-mykobakterielle impfstoffe | |
JP2005523318A5 (es) | ||
CA2153391A1 (en) | Inducing Cytotoxic T Lymphocyte Responses | |
EP0755259A4 (en) | CHIMERAL cDNA CLONES OF THE VIRUS OF INFECTIOUS BURSAL DISEASE, EXPRESSION PRODUCTS AND Vaccines Based On Them | |
RU94038050A (ru) | Рекомбинантный вирус, вектор, вакцина, способ иммунизации, клетка-хозяин | |
HUP9901546A2 (hu) | Helicobacter pylori antigének és vakcinakészítmények | |
JPS5936698A (ja) | B型肝炎ウイルス遺伝子を組込んだ組換えdnaおよび形質転換動物細胞 | |
US20230364211A1 (en) | Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine | |
Gill | Nanocarriers, nanovaccines, and nanobacteria as nanobiotechnological concerns in modern vaccines | |
Liang et al. | Protective immunity induced by recombinant protein CPSIT_p8 of Chlamydia psittaci | |
Liu et al. | A tetrahedral framework nucleic acid based multifunctional nanocapsule for tumor prophylactic mRNA vaccination | |
JP5710254B2 (ja) | 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用 | |
Mukai et al. | HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinations | |
ATE223492T1 (de) | Mutanten des infektiösen rinder rhinotracheitis- virus und impfstoffe | |
Chin et al. | Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants | |
Basirnejad et al. | Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant | |
EP0704529A3 (en) | Vaccine against rabbit hemorrhagic disease virus | |
Choi-Miura et al. | The role of HDL consisting of SP-40, 40, apo AI and lipids in the formation of SMAC of complement | |
WO2000041717A3 (en) | Chorionic gonadotropin dna vaccines and methods | |
WO2023142283A1 (zh) | 一种新型冠状病毒mRNA疫苗及其制备方法与应用 |